Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Mölndal, Sweden, May 3[rd], 2022 - Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces today that the company has appointed Karin Ganlöv as Chief Medical Officer (CMO). Karin Ganlöv joined the company in April and will be part of the management team.
Karin Ganlöv is a board-certified specialist physician in cardiothoracic surgery with almost a decade of clinical experience. She has 20 years of experience in the life science industry and joins most recently from a position as VP Global Medical Affairs at Cochlear, a global leader in implantable hearing solutions. Further, Karin Ganlöv has experience from positions as Chief Medical Officer at the Swedish biotech company Isofol Medical, Global Medical and Health Economics Director at Mölnlycke Health Care, Nordic Medical Director at ALK-Albelló Nordic and Nordic Medical Science Physician.
"Integrum's products are based on a unique approach of using osseointegration for prostheses, to simplify the life for amputees and, in so, increase their quality of life. Integrum also works with the product's entire life cycle, from innovation and product development via full-scale manufacturing, registration and market launch, to marketing and sales. I look forward to take part in this fast-growing company which has great opportunities in the future," says Karin Ganlöv.
The CMO position entails medical affairs responsibility for products on the market. This includes, among other duties, conducting device evidence-based market surveillance, including post-market clinical follow-ups, validating relevant clinical information associated to the product, and ensuring clinical assessments when needed. Karin Ganlöv succeeds Rickard Brånemark, who has held the role as CMO since 1998, the last few years on a consultancy basis. Rickard Brånemark, who is chairman of the board of Integrum, remains as Chief Scientific Officer in the company with a focus on research & development.
"We are happy to welcome Karin Ganlöv as our new Chief Medical Officer. Our innovative products are increasingly being used to treat patients around the world, and her broad experience, in both the surgical and the implant area, will be of pivotal importance in the dialogue with the scientific community and in assessing our products on the market," comments María López, Integrum's CEO.
Integrum's OPRA[TM] Implant System is a bone-anchored system based on osseointegration. As the prostheses are directly attached to the bone, the use of a socket is avoided, leading to fewer complications and better quality of life for the patient.